Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct;37(5):977-992.
doi: 10.1016/j.hoc.2023.04.019. Epub 2023 May 25.

Renal Cell Carcinoma of Variant Histology: Biology and Therapies

Pavlos Msaouel  1 , Giannicola Genovese  2 , Nizar M Tannir  3
Affiliations
Review

Renal Cell Carcinoma of Variant Histology: Biology and Therapies

Pavlos Msaouel et al. Hematol Oncol Clin North Am. 2023 Oct.

Abstract

The term variant histology renal cell carcinomas (vhRCCs), also known as non-clear cell RCCs, refers to a diverse group of malignancies with distinct biologic and therapeutic considerations. The management of vhRCC subtypes is often based on extrapolating results from the more common clear cell RCC studies or basket trials that are not specific to each histology. The unique management of each vhRCC subtype necessitates accurate pathologic diagnosis and dedicated research efforts. Herein, we discuss tailored recommendations for each vhRCC histology informed by ongoing research and clinical experience.

Keywords: Chromophobe renal cell carcinoma; Collecting duct carcinoma; MiTF translocation renal cell carcinoma; Nonclear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal medullary carcinoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Forest plots summarizing the reported objective responses to immune checkpoint–based therapies of papillary and chromophobe renal cell carcinomas.
See this image and copyright information in PMC

References

    1. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds. Clin Genitourin Cancer. 2021;19(2):103–116. - PMC - PubMed
    1. Rini BI, Battle D, Figlin RA, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019;7(1):354. - PMC - PubMed
    1. Msaouel P, Hong AL, Mullen EA, et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer. 2019;17(1):1–6. - PMC - PubMed
    1. Wilson NR, Wiele AJ, Surasi DS, et al. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021;19(6):e401–e408. - PubMed
    1. Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012;62(6):1013–1019. - PMC - PubMed

Publication types